PHYSIOTHERAPY BASED APPROACHES TO PATIENT REHABILITATION AND DENTAL EXPERTISE FOR JAW AND FACIAL PAIN
With
Darron Goralsky,
CEO & Clinical Director
Melbourne TMJ & Facial Pain Centre
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | November 2025
Darron Goralsky is the Founder, CEO and Clinical Director of Melbourne TMJ & Facial Pain Centre, one of Australia’s leading multidisciplinary clinics dedicated to the assessment and management of temporomandibular disorders (TMD) and craniofacial pain.
With over 30 years of experience treating TMJ, facial and neck-related conditions, Darron originally trained as a Physiotherapist in South Africa, completing post graduate certifications in Manipulative Therapy. After his arrival in Melbourne he then continued with studies in Craniosacral Therapy. Early in his career, Darron identified a major gap in how jaw and facial pain conditions were managed—recognising the need for a collaborative approach that integrates manual therapy and other physiotherapy based approaches to patient rehabilitation, and dental expertise.
This insight led to the development of the Goralsky Craniomandibular Method (GCMM), a structured multidisciplinary protocol combining physiotherapy principles with dental and medical collaboration. Darron has lectured to many dental and allied health groups, was part of a 4 person lecture team for a one day course on TMD for the University of Melbourne’s Dental School, and presented at the 2019 ANZAOP Conference. In 2024, Darron was an invited speaker at the Myofocus Functional Health Symposium in Melbourne, presenting on multidisciplinary management of TMD and orofacial pain. Darron has also presented a 5-hour Masterclass for dentists as part of Dr Damian Teo’s Mini Residency in TMD & Sleep for the last 5 years. Building on this momentum, he developed and successfully delivered his inaugural 2-day intensive professional education program for dental professionals, The 5-Step TMD Protocol Course, in October 2025.
A passionate educator and mentor, Darron now focuses on training and developing clinicians in his evidence-based approach. His growing team includes TMJ physiotherapists, osteopaths, dentists, and orofacial myofunctional therapists, a breathing educator and a GP working collaboratively to deliver comprehensive patient care. Darron is an active member of the Australian Physiotherapy Association (APA), the American Academy of Craniofacial Pain (AACP), and the Australia and New Zealand Academy of Orofacial Pain (ANZAOP).
Source: Supplied and adapted
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
-
Early detection & surveillance guides for pancreatic cancer
Pancreatic cancer remains one of Australia’s deadliest cancers, with five-year survival rates hovering at just 14%, with little improvement over several decades. Often called the ‘silent killer’, the disease frequently presents with minimal or vague symptoms, resulting in late diagnoses and poor outcomes. Pancare Foundation is leading the rollout of new clinical resources and surveillance guides to support healthcare professionals in identifying at-risk patients and promoting early detection.
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
